Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Aicardi Goutières Syndrome
NCT03921554Phase 2Completed
- Start
- Jun 2019
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in Aicardi-Goutières syndrome (AGS). Primary endpoint: Aicardi Goutières Syndrome Scale at 52 weeks. Started Jun 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
Aicardi-Goutières syndrome (AGS)
Beyond the preview
Go deeper on NCT03921554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921554.